Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

LEGEND BIOTECH CORPORATION

(LEGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Legend Biotech Submits New Drug Application for Myeloma Therapy to Japanese Regulator

12/06/2021 | 09:56am EST


ę MT Newswires 2021
All news about LEGEND BIOTECH CORPORATION
01/09LEGEND BIOTECH : 40th Annual J.P. Morgan Healthcare Conference
PU
01/07NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
01/06Morgan Stanley Downgrades Legend Biotech to Equalweight from Overweight, Keeps $51 Pric..
MT
01/04LEGEND BIOTECH : to Participate in the 40th Annual J.P. Morgan Healthcare Conference - For..
PU
01/04Legend Biotech to Participate in the 40th Annual J.P. Morgan Healthcare Conference
BU
2021LEGEND BIOTECH : Announces Appointment of Dr. Ying Huang to the Board of Directors - Form ..
PU
2021Legend Biotech Announces Appointment of Dr. Ying Huang to the Board of Directors
BU
2021Legend Biotech Announces Appointment of Ying Huang to the Board of Directors
CI
2021Piper Sandler Starts Legend Biotech at Overweight With $66 Price Target
MT
2021Nasdaq-listed Legend Biotech Raises $345 Million in Share Offering
MT
More news
Analyst Recommendations on LEGEND BIOTECH CORPORATION
More recommendations
Financials (USD)
Sales 2021 97,4 M - -
Net income 2021 -400 M - -
Net cash 2021 297 M - -
P/E ratio 2021 -22,1x
Yield 2021 -
Capitalization 5 868 M 5 868 M -
EV / Sales 2021 57,2x
EV / Sales 2022 17,7x
Nbr of Employees 1 000
Free-Float -
Chart LEGEND BIOTECH CORPORATION
Duration : Period :
Legend Biotech Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LEGEND BIOTECH CORPORATION
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 38,12 $
Average target price 64,00 $
Spread / Average Target 67,9%
EPS Revisions
Managers and Directors
Ying Huang Director, Chief Executive & Financial Officer
Ye Wang Chairman
Frank Fan Chief Scientific Officer
Corsee Dating Sanders Independent Director
Darren Ji Independent Director
Sector and Competitors
1st jan.Capi. (M$)
LEGEND BIOTECH CORPORATION-18.22%5 868
GILEAD SCIENCES, INC.-5.19%86 352
REGENERON PHARMACEUTICALS-4.49%63 067
VERTEX PHARMACEUTICALS3.42%57 743
WUXI APPTEC CO., LTD.-7.49%50 700
BIONTECH SE-39.30%37 796